Lupin receives EIR from USFDA for Nagpur facility

18 Oct 2019 Evaluate

Lupin has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Nagpur facility. The facility was inspected by the USFDA between August 5, 2019 and August 8, 2019. The inspection for the oral solid facility at Nagpur closed without any Form 483 observation. The Nagpur facility is company’s largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance. 

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×